R&D Pipeline
Guided by innovation and internationalization, Fosun Pharma increases its investment in R&D and the introduction of scientific research personnel, enriches its innovative product pipelines, improves its R&D and clinical trial capacities for new drugs, and speeds up the R&D and transformation of innovative technologies and products through diverse and multi-level cooperation models, such as independent R&D, co-development, in-licensing, and in-depth incubation.
Major Drugs under Development
As of March 2026, Fosun Pharma has 80+ programs in clinical development (by indication)
-
- 16
- Marketed products
-
- 32
- Programs in pivotal trials or at the NDA/ BLA stage
-
- 53
- Oncology programs
-
- 33
- Non-oncology programs (immuno-inflammatory diseases, neurodegenerative diseases, etc.)
For more specific information about Henlius's pipeline, please visit the official website of Henlius